Macro Biologics

3:15 PM - 3:30 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
Macro Biologics’ innovative technology platform creates synthetic biological polymers (macro biologics) for breakthrough therapeutics, next-generation medical devices, and advanced biomaterials safe for the environment. Our first class of synthetic macro biologics, Amicidins, combine a beneficial physical mode-of-action (barrier or surfactant) and broad microbicidal mode-of-action, including against antibiotic resistant bacteria. Their composition (amino acids), size, and self-assembly into multimers, yield a high level of performance and safety when applied to exposed tissues. Our first focus is prevention and treatment of life-threating infections in surgery & trauma – INDs are in preparation for Amicidin-α Surgical and Amicidin-β Solution; human clinical trials are expected to follow. Going forward, we anticipate Amicidins will go into a wide variety of products ranging from human therapeutics and devices to veterinary medicine / pet care to consumer health and cosmetics.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Macro Biologics has four products in development: Amicidin-alpha Surgical, Amicidin-alpha PFC (Prolonged Field Care), Amicidin-beta Solution, and Amicidin-beta/EF (Extended Formulation). Amicidin-alpha Surgical is designed to prevent infection, as an adjunct to surgical procedures. It combines physical barrier to block and microbicidal activity to kill. Amicidin-alpha PFC (supported by U.S. DoD) is designed for prolonged field care of injured warfighters. It is a dry powder formulation designed to protect wounds for up to 72h. Amicidin-beta Solution (supported by CARB-X) is designed to treat infection, as an adjunct to surgical procedures. It combines surfactant activity to cleanse with microbicidal activity to kill. Amicidin-beta/EF (supported by UK GAMRIF & CARB-X) is designed for traumatic wounds and emergency caesarean delivery, including in low- and middle-income countries.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Macro Biologics